Delcath Systems (DCTH)
(Delayed Data from NSDQ)
$6.45 USD
-0.28 (-4.16%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $6.45 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Brokerage Reports
Delcath Systems, Inc. [DCTH]
Reports for Purchase
Showing records 1 - 20 ( 149 total )
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Positive HEPZATO KIT Adoption Trends Expected to Continue; New PT $20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
3Q23 Recap - Launch Targeted for Early 2024 (No Change)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Expect HEPZATO Launch in January 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Hepzato Gained FDA Approval; Potential Launch in 4Q23; New PT $18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Preparations For Hepzato Launch Underway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
PDUFA Date for HEPZATO Set; Dilution-Led Lower PT To $17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
4Q22 Recap - NDA Accepted and Balance Sheet Fortified
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Filing Complete; Acceptance Decision in 30 Days
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
M-PHP Plus Checkpoint Inhibitors Shows Promise in Metastatic Uveal Melanoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
NDA Submission Underway; EU Revenues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S